Table 1.
Clinical Characteristics of the Hepatocellular Carcinoma Patients in the Study
| Characteristics | Values |
|---|---|
| Patients, n | 127 |
| Sex (male) | 108 (85.0%) |
| Age, year (≥45) | 72 (56.7%) |
| BMI (≥24kg/m2) | 43 (33.9%) |
| Diabetes mellitus | 10 (7.9%) |
| HBsAg (positive) | 115 (80.6%) |
| HBV-DNA(≥5×102 IU/mL) | 89 (70.1%) |
| Child-Pugh class (A stage) | 121 (95.3%) |
| Total bilirubin (≥17.1 µmol/L) | 40 (31.5%) |
| ALB (≥35 mg/L) | 111 (87.4%) |
| ALT (≥40 U/L) | 59 (46.5%) |
| AST (≥40 U/L) | 67 (52.8%) |
| PT (≥13 s) | 62 (48.8%) |
| INR (≥1) | 98 (77.2%) |
| Platelet count (≥225×109/L) | 61 (48.0%) |
| CTCs (>5/5 mL) | 77 (60.6%) |
| AFP (≥200 µg/mL) | 76 (59.8%) |
| Tumor size (≥5 cm) | 88 (69.3%) |
| Multiple lesions (yes) | 37 (29.1%) |
| Inflow blood occlusion (yes) | 95 (74.8%) |
| Tumor capsule (complete) | 100 (78.7%) |
| Resection margin (≥1cm) | 38 (78.7%) |
| MVI (positive) | 79 (62.2%) |
| Histological grade (≥3) | 69 (54.3%) |
| Histological cirrhosis (yes) | 48 (37.8%) |
| Satellite nodule (yes) | 27 (21.3%) |
| Ki67 (≥35%) | 59 (46.5%) |
| Postoperative adjuvant therapy (yes) | 55 (43.3%) |
Note: Values shown are n (%).
Abbreviations: AFP, alpha-fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CTCs, circulating tumor cells; HBV-DNA, hepatitis B virus DNA; HBsAg, hepatitis B surface antigen; INR, international normalized ratio; MVI, microvascular invasion; PT, prothrombin time.